Semi-Annual Changes to the NASDAQ Biotechnology Index

New York - 13 May 2013

The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq:NBI), which will become effective prior to market open on Monday, May 20, 2013.

The following eleven securities will be added to the Index: ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD); Albany Molecular Research, Inc. (Nasdaq:AMRI); Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC); Clovis Oncology, Inc. (Nasdaq:CLVS); Furiex Pharmaceuticals, Inc. (Nasdaq:FURX); Hyperion Therapeutics, Inc. (Nasdaq:HPTX); NewLink Genetics Corporation (Nasdaq:NLNK); Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX); Repligen Corporation (Nasdaq:RGEN); Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP); and Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP).

The Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November.

As a result of the re-ranking, the following four securities will be removed from the Index: Affymax, Inc. (Nasdaq:AFFY); BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX); Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT); and Savient Pharmaceuticals Inc. (Nasdaq:SVNT).

The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

Become a bobsguide member to access the following

1. Unrestricted access to bobsguide
2. Send a proposal request
3. Insights delivered daily to your inbox
4. Career development